Rx Peps Direct vs Henry Meds

“Henry Meds alternative” is one of the most common searches in peptide telehealth, and most of the people typing it are not unhappy with Henry. They have simply outgrown a menu built around GLP-1 weight loss. This is an honest, side-by-side comparison of the two services across pricing, formulary, formulations, state coverage, the clinician model, and the pharmacy partner. We sell peptides, so read the “when Henry makes sense” section as proof that this is a real comparison and not a one-sided pitch.

1. What Henry Meds offers (GLP-1 weight loss and TRT)

Henry Meds built its brand on accessible GLP-1 weight loss. Its center of gravity is compounded GLP-1 medication (semaglutide and tirzepatide class), delivered through a clean, consumer-friendly subscription, alongside oral GLP-1 options, compounded liraglutide, and phentermine. Around that core, Henry adds testosterone replacement therapy (TRT), which Rx Peps Direct does not offer. What Henry does not publicly offer is a compounded-peptide formulary: its site does not list or price sermorelin, NAD+, BPC-157, or the recovery, growth-hormone, and longevity peptides Rx Peps Direct carries.

The strength of this model is focus. A patient who wants a GLP-1 and maybe one recovery peptide gets a tidy, low-decision experience: pick the plan, complete intake, and the medication arrives on a recurring schedule. Henry is not trying to be a deep peptide pharmacy, and for the GLP-1-first buyer that restraint is a feature, not a limitation.

The GLP-1 evidence base behind that core is genuinely strong. According to PubMed, the SURMOUNT-1 phase 3 randomized trial of once-weekly tirzepatide produced mean weight reductions of roughly 15 to 21 percent over 72 weeks depending on dose (Jastreboff et al., 2022). That is the science Henry is packaging, and it is real.

2. What Rx Peps Direct offers (full peptide formulary)

Rx Peps Direct approaches the same patient from the opposite direction. Instead of leading with a single weight loss drug and bolting on a few extras, it publishes a 65-plus product formulary with per-vial pricing on every item. GLP-1s are part of the selection, but so are growth hormone secretagogues, recovery stacks, sexual health peptides, longevity compounds, and a small cognitive line.

The categories Henry does not meaningfully cover are where Rx Peps Direct is built to win:

One important honesty note up front: Rx Peps Direct writes the prescription only. The medication is filled, shipped, and billed by a licensed U.S. 503A compounding pharmacy. Rx Peps Direct does not dispense, ship, or sell the medication itself. That two-party structure is the backbone of the pricing model described below.

3. Pricing: where Rx Peps Direct wins

Henry Meds bundles medication, provider access, and shipping into one recurring monthly subscription. Rx Peps Direct splits it: a flat $39 medical review (one review can cover up to three different peptides) plus the medication billed per vial by the pharmacy at wholesale. On the medications the two actually share, the GLP-1s, Rx Peps Direct is far cheaper.

GLP-1 cost, head to head

This is the comparison most patients come for. Henry’s publicly listed GLP-1 prices are a flat monthly subscription. Rx Peps Direct is the $39 medical review plus the actual per-vial dose.

Two things stand out. Rx Peps Direct injectable semaglutide starts at $48.60 all-in, about a quarter of Henry’s $179 entry plan and a sixth of its $297 standard plan, and is lower at every dose. And Henry only offers tirzepatide as an oral dissolving tablet, while Rx Peps Direct prescribes injectable tirzepatide, the clinically standard route with far better absorption, and at $75 to $237 all-in it is cheaper than Henry’s roughly $349 to $449 per month oral version at every dose.

For scale, branded Zepbound now sells to self-pay patients for $299 to $449 a month through LillyDirect, so a bundled compounded plan at $349 to $449 is no longer a discount to the brand. The discount survives only when the medication is billed at wholesale.

The GLP-1 starter plan (first 3 months)

Most people start low and titrate up. Here is a standard 3-month semaglutide start, using Rx Peps Direct’s published vial ladder plus the $39 medical review, against Henry’s $297 standard injectable subscription (Henry’s $179 microdose plan would total $537 over the same three months, still about $356 more than Rx Peps Direct):

That is about $710 saved in the first three months alone, before you have even reached a full dose, and the gap only widens over a year.

The peptides Henry does not carry

Outside GLP-1s and TRT, Henry’s site does not publicly offer or price compounded peptides. Rx Peps Direct publishes per-vial pricing on sermorelin, NAD+, BPC-157, and 50-plus others Henry does not carry, each available on the same $39 medical review.

Sermorelin, NAD+, and BPC-157 are not on Henry’s menu at all. At Rx Peps Direct sermorelin is the $80 vial plus a $39 medical review, NAD+ is $100, and you can add a second or third peptide on the same review, an entire category of therapy Henry simply does not offer.

One thing Henry has that Rx Peps Direct does not: TRT

In fairness, Henry Meds offers testosterone replacement therapy (TRT), and Rx Peps Direct does not. If a bundled GLP-1-plus-testosterone program under one roof is what you want, that is a genuine reason to choose Henry. Rx Peps Direct stays focused on compounded peptides and does not prescribe testosterone. For everything in the peptide and GLP-1 column, though, Rx Peps Direct is both broader and cheaper.

4. Peptide breadth comparison

Breadth is the clearest dividing line. Henry Meds carries a small, curated set of peptides anchored to GLP-1 weight loss. Rx Peps Direct lists 65-plus peptide and wellness formulations across the full therapeutic range.

If your needs stop at a GLP-1 plus sermorelin or NAD+, the breadth gap is irrelevant to you. If you run a multi-system protocol, or want BPC-157 and recovery peptides Henry does not carry, it is the whole story.

5. Carrier formulations

A detail most comparisons skip: how the peptide is formulated. The GLP-1s Rx Peps Direct prescribes are compounded with carrier additives rather than as a bare molecule. The formulary pairs semaglutide and tirzepatide with B-12 or with B6 plus glycine carriers depending on the variant. This is a formulation choice the 503A pharmacy makes, not a purity claim. We do not publish HPLC purity data, and our certificates of analysis cover sterility and endotoxin, so we describe carriers factually rather than implying they make the product “purer.”

Injectable peptides prescribed through Rx Peps Direct arrive pre-reconstituted, FedEx overnight, in a reusable cooled travel case, fulfilled by the pharmacy. You do not mix anything yourself. Henry Meds also ships ready-to-use formats for its GLP-1 line. The meaningful difference is variety: Rx Peps Direct exposes multiple carrier and dose formats per molecule, while Henry keeps its formats narrow and standardized in service of its simpler menu.

6. State coverage

Henry Meds serves most states for its weight loss core but does not publish a state list; third-party trackers count about nine states where it is unavailable. Rx Peps Direct’s peptide service is available in 28 states plus Washington, DC as of September 2026, a footprint determined by where its prescribers hold licensure. This is an honest limitation: a service built on a small prescriber roster covers fewer states than a large weight loss brand with a wide clinician network.

The states that matter to you are the ones where both operate, since that overlap is where a real head-to-head choice exists. Because each company updates its map on its own schedule, the only reliable move is to confirm your specific state on each site before committing. Do not assume that nationwide GLP-1 availability implies nationwide peptide availability; they are governed by different licensure and supply constraints.

7. Clinician model

Both services use licensed telehealth providers and asynchronous intake rather than in-person visits. The difference is positioning. Henry Meds runs a high-volume, weight-loss-first clinician model optimized for a narrow set of GLP-1 protocols, which keeps the patient experience simple and repeatable.

Rx Peps Direct’s providers review intakes across a much wider formulary, which means more provider judgment per case: a patient asking for a GH secretagogue stack plus a recovery peptide needs a different review than a single GLP-1 request. Rx Peps Direct medical oversight is led by Medical Director Dr. Jonathan Snipes (NPI 1821250077), with Kim Callender, FNP-BC, as lead prescriber. Neither model is “better” in the abstract; a narrow menu rewards a streamlined clinician flow, and a broad menu rewards more individualized review.

8. Pharmacy partner comparison

Rx Peps Direct prescriptions are filled by a single licensed 503A pharmacy in Texas. That pharmacy fills, ships, and collects payment for the medication, while Rx Peps Direct handles only the prescription and the $39 medical review. The pharmacy is identified to each patient at approval, and its certificate-of-analysis scope (sterility and endotoxin) is published, so a patient can see what was tested before they use it.

Henry Meds works with its own compounding pharmacy network for fulfillment, bundled inside the subscription. For most buyers the bundling is convenient. For a buyer who wants one consistent pharmacy and a published testing scope, Rx Peps Direct’s single-pharmacy model is more transparent by design. We do not claim purity beyond what the COAs actually cover.

9. Intake process

The two intakes are structurally similar and differ mainly in scope:

1. Online health history. Both services collect medical history, current medications, and goals through a structured online form. No in-person clinic visit is required by either.
2. Medical review. Henry’s review is tuned for GLP-1 eligibility. Rx Peps Direct’s review spans the broader formulary and screens for peptide-specific contraindications.
3. Prescription and fill. Henry routes the script into its bundled subscription fulfillment. Rx Peps Direct sends the prescription to the pharmacy, which fills and ships pre-reconstituted product FedEx overnight in a reusable cooled travel case and collects the medication payment separately.
4. Billing. Henry charges one recurring subscription. Rx Peps Direct charges a one-time $39 medical review, with the pharmacy billing the medication per vial.

Note that there is no script “transfer” between the services. Moving from Henry to Rx Peps Direct means completing a fresh Rx Peps Direct intake and a new independent medical review, not porting an existing prescription.

10. When Henry makes sense, when RxPeps makes sense

The honest version of this comparison is that the two services are optimized for different buyers.

When Henry Meds makes sense

• You primarily want a GLP-1 weight loss plan and value a single bundled monthly charge over itemized pricing.
• Your protocol stops at a GLP-1 plus, at most, sermorelin or NAD+.
• You want the simplest possible decision and a polished consumer experience, and you live in a state Rx Peps Direct does not yet cover.

When Rx Peps Direct makes sense

• You run a multi-peptide protocol spanning GH secretagogues, recovery, sexual health, or cognitive categories that Henry does not carry.
• You want transparent per-vial pricing and no recurring membership, paying a flat $39 medical review plus pharmacy cost.
• You want to know the licensed 503A pharmacy and the certificate-of-analysis scope behind your medication, and you live in one of the 28 covered states or Washington, DC.

11. Side-by-side table

A note on evidence quality, because honesty cuts both ways. The GLP-1 weight loss data both companies rely on is strong and trial-backed. The growth hormone secretagogue data (sermorelin, tesamorelin, CJC-1295/Ipamorelin) is real but more modest, with tesamorelin the best-evidenced of the group. The recovery peptides (BPC-157, TB-500) rest mostly on preclinical and anecdotal support with thin or absent human randomized data, and the cognitive peptides are earlier still. Neither service can honestly promise outcomes for the thinner-evidence categories, and any that does is overselling.